Evaluation of novel nano-pharmaceuticals in targeted drug delivery for cancer therapy

Read full text Summarise with VIRAT
Authors: Maximilian Weber, Katharina Hoffmann
Cited by: 0
References: 15

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Can nanotechnology truly overcome the persistent challenges that plague conventional cancer chemotherapy? This research set out to evaluate six distinct nano-pharmaceutical formulations designed for targeted drug delivery in oncology settings. We synthesized and characterized PEG-PLGA nanoparticles, liposomal doxorubicin constructs, fourth-generation dendrimers, solid lipid nanoparticles, albumin-based carriers, and chitosan nanoparticles at two academic institutions in southern Germany between March 2022 and November 2023. Particle sizes ranged from 68.4 nm to 247.3 nm as measured by dynamic light scattering, with polydispersity indices below 0.28 for all preparations. Encapsulation efficiency peaked at 92.1% for liposomal formulations and reached 87.3% for PEG-PLGA constructs. In vitro release profiles demonstrated sustained drug liberation over 96 hours, with PEG-PLGA nanoparticles releasing 93.4% of their payload compared to near-complete release of free doxorubicin within 24 hours. Cytotoxicity assays performed on five cancer cell lines (MCF-7, HeLa, A549, HepG2, and PC-3) revealed that nanoencapsulated doxorubicin reduced cell viability by 31.2% to 47.8% more than the free drug at equivalent concentrations. Liposomal formulations exhibited the strongest anticancer activity with IC50 values 2.3-fold lower than free doxorubicin across all tested cell lines. Zeta potential measurements confirmed colloidal stability, ranging from -18.7 mV to -32.4 mV. These findings indicate that lipid-based and polymeric nanocarriers can markedly improve the therapeutic index of doxorubicin, though translation to clinical application demands further pharmacokinetic profiling and in vivo validation.

Fields of Study & Subjects

Nanoparticle-Based Drug Delivery Advanced Drug Delivery Systems Dendrimers and Hyperbranched Polymers

Publication details

Journal / source
International Journal of Pharmacology and Clinical Research
Volume
8
Issue
1
Pages
63–68
Publication date
1 January 2026
Language
EN